Jody L. Green, PhD, explains how regulatory decisions shape medication safety amid uptake of OTC drugs. Green also highlights ...

Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.

Chemists from St. Petersburg University has developed a new family of luminescent iridium complexes that, for the first time, realize a unique mechanism of photoactivated proton transfer. In the ...

Evidence continues to mount suggesting that GLP-1 drugs like Ozempic and Wegovy may help people cut back on cigarettes, ...

Many biological functions are regulated by the switching on and off of mechanisms triggered by the matching of a keyhole ...

The FDA has outlined a proposed approval pathway for customized drugs and gene-editing therapies designed for rare and ...

State laws that ban insurance prior authorization for buprenorphine—a leading medication for opioid use disorder—may not help more patients stay in treatment for the recommended minimum of 180 days, ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now.

TGIF, and welcome to Health Brief. As is customary on Fridays, I’m wondering what’s on your mind. This Feedback Friday, shoot me a note, and let me know about a topic you’d like to hear more about.

The FDA lost about 20% of its workforce after Trump took office last year. Now it wants to shrink approvals from as long as 29 months to as low as six.

If you're one of the millions of women who've found success with GLP-1 medications-whether you've lost a significant amount of weight or finally gotten your blood sugar under control-you're probably ...

A decades-old warning rooted in flawed research kept millions of women from life-changing treatment, officials say.